SOX9, the Master Regulator of Lung Cancer, and a Therapeutic Approach
Journal of Biochemical and Molecular Toxicology · 2026-05 · 40 (5)
DOI: 10.1002/jbt.70862 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 04.05.2026. Verfasst von Yongli Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Beihua University Affiliated Hospital, Jilin, Jilin City, Jilin, China. Hauptthemen laut MEDLINE: SOX9 Transcription Factor, Lung Neoplasms, Gene Expression Regulation, Neoplastic. Die Arbeit nennt 77 Literaturangaben.
Abstract (Originalsprache)
Dysregulation of transcription factors is a hallmark of lung tumorigenesis, and Sex‐determining region Y‐box 9 (SOX9) has emerged as a putative master regulator at the intersection of development and malignancy. Building on evidence from lung and other solid tumors, we summarize how aberrant SOX9 expression, shaped by epigenetic modification, post‐translational regulation, and non‐coding RNAs, drives proliferation, survival, invasion, and therapy resistance. In lung cancer, SOX9 appears to orchestrate a stem‐like, plastic cell state, promoting epithelial‐mesenchymal transition (EMT), metastatic dissemination, and remodeling of the tumor microenvironment (TME). These context‐dependent functions position SOX9 both as an oncogenic driver and, in selected settings, as a modulator of treatment response. This review integrates current mechanistic and translational data to frame SOX9 as a clinically actionable node within key signaling circuits relevant to non‐small cell and small cell lung cancer. We highlight emerging strategies that directly or indirectly target SOX9, including interference with upstream pathways, epigenetic reprogramming, and RNA‐based approaches designed to modulate SOX9 expression or activity. Finally, we propose SOX9 as a dual biomarker and therapeutic handle to guide rational combination therapies aimed at overcoming drug resistance and improving patient stratification. By connecting molecular insight with unmet clinical needs, this article outlines a conceptual roadmap for SOX9‐centered therapeutic approaches in lung cancer. A key novelty of this review is the integration of SOX9‐centered molecular mechanisms with therapeutic resistance, biomarker potential, and emerging indirect targeting strategies in lung cancer, thereby providing a translational framework for future SOX9‐guided interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beihua University Affiliated Hospital, Jilin, Jilin City, Jilin, China.
- Changchun Central Hospital, Changchun, Jilin, China.
ORCID-Profile: Ying Jia
Zitieren
APA
Chen, Y., Meng, X., Chen, Y., & Jia, Y. (2026). SOX9, the Master Regulator of Lung Cancer, and a Therapeutic Approach. Journal of Biochemical and Molecular Toxicology, 40(5). https://doi.org/10.1002/jbt.70862
Vancouver
Chen Y, Meng X, Chen Y, Jia Y. SOX9, the Master Regulator of Lung Cancer, and a Therapeutic Approach. Journal of Biochemical and Molecular Toxicology. 2026;40(5). doi:10.1002/jbt.70862
BibTeX
@article{Chen2026,
author = {Chen, Yongli and Meng, Xiaoming and Chen, Yanling and Jia, Ying},
title = {SOX9, the Master Regulator of Lung Cancer, and a Therapeutic Approach},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2026},
volume = {40},
number = {5},
doi = {10.1002/jbt.70862}
}
EUVIMED